Nancy Miller-Rich
Direttore/Membro del Consiglio presso ALDEYRA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Nancy Miller-Rich
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALDEYRA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 13/01/2020 | - |
Independent Dir/Board Member | 13/01/2020 | - | |
4D MOLECULAR THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 18/11/2020 | - |
Independent Dir/Board Member | 18/11/2020 | - | |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Direttore/Membro del Consiglio | 06/03/2018 | - |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Presidente | - | - |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - | - |
Independent Dir/Board Member | - | - | |
Miller-Rich Associates LLC | Amministratore Delegato | 01/01/2017 | - |
Fondatore | 01/01/2017 | - | |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Presidente | 23/02/2022 | - |
Direttore/Membro del Consiglio | 09/08/2021 | 23/02/2022 | |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Nancy Miller-Rich
Precedenti posizioni note di Nancy Miller-Rich
Società | Posizione | Inizio | Fine |
---|---|---|---|
INTERCEPT PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 24/04/2018 | 08/11/2023 |
Independent Dir/Board Member | 24/04/2018 | 08/11/2023 | |
░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Nancy Miller-Rich
Ithaca College | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 14 |
Irlanda | 2 |
Canada | 2 |
Posizioni
Director/Board Member | 9 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 13 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 4 |
---|---|
MERCK & CO., INC. | Health Technology |
ALDEYRA THERAPEUTICS, INC. | Health Technology |
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
Aziende private | 10 |
---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
UDG Healthcare Ltd. (Dublin)
UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services UDG Healthcare Plc engages in the supply and distribution of pharmaceutical and medical products. It operates through the following segments: Ashfield, Sharp, and Aquilant. The Ashfield segment provides commercialization services for the pharmaceutical and healthcare industry. The Sharp segment offers contract packaging and clinical trial packaging services. The Aquilant segment involves. outsourced sales, marketing, distribution, and engineering services to the medical and scientific sectors. The company was founded in 1948 and is headquartered in Dublin, Ireland. | Commercial Services |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
TEN63 Therapeutics
TEN63 Therapeutics Pharmaceuticals: MajorHealth Technology TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation. | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Health Technology |
Miller-Rich Associates LLC |
- Borsa valori
- Insiders
- Nancy Miller-Rich
- Esperienza